Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo

References

• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin2010605 277 30020610543
   PubMed Web of Science ®Google Scholar
• KanthalaSPallerlaSJoisSCurrent and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptorsFuture Oncol2015115 865 87825757687
   PubMed Web of Science ®Google Scholar
• SridharSSSeymourLShepherdFAInhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancerLancet Oncol200347 397 40612850190
   PubMed Web of Science ®Google Scholar
• PallisAGSyrigosKTargeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: current status and future challengesCancer Treat Rev2012387 861 86722217701
   PubMed Web of Science ®Google Scholar
• GreenhalghJDwanKBolandAFirst-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerCochrane Database Syst Rev20165 CD01038327223332
   PubMed Web of Science ®Google Scholar
• WuYLLeeJSThongprasertSIntercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trialLancet Oncol2013148 777 78623782814
   PubMed Web of Science ®Google Scholar
• AbernethyAPArunachalamABurkeTReal-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology settingPLoS One2017126 e017842028644837
   PubMed Web of Science ®Google Scholar
• HeistRSFirst-line systemic therapy for non-small cell lung cancerHematol Oncol Clin North Am2017311 59 7027912834
   PubMed Web of Science ®Google Scholar
• WangSPengLLiJA trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancerPLoS One201383 e5591723520448
   PubMed Web of Science ®Google Scholar
• YardenYSliwkowskiMXUntangling the ErbB signalling networkNat Rev Mol Cell Biol200122 127 13711252954
   PubMed Web of Science ®Google Scholar
• LiuTCJinXWangYWangKRole of epidermal growth factor receptor in lung cancer and targeted therapiesAm J Cancer Res201772 187 202 eCollection 201728337370
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol2012133 239 24622285168
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multi-centre, open-label, randomised, phase 3 studyLancet Oncol2011128 735 74221783417
   PubMed Web of Science ®Google Scholar
• MadniABatoolANoreenSNovel nanoparticulate systems for lung cancer therapy: an updated reviewJ Drug Target2017256 499 51228151021
   PubMed Web of Science ®Google Scholar
• WojtkowiakJWVerduzcoDSchrammKJGilliesRJDrug resistance and cellular adaptation to tumor acidic pH microenvironmentMol Pharm201186 2032 203821981633
   PubMed Web of Science ®Google Scholar
• ChengRFengFMengFDengCFeijenJZhongZGlutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene deliveryJ Control Release20111521 2 1221295087
   PubMed Web of Science ®Google Scholar
• CaiZZhangHWeiYWeiYXieYCongFReduction- and pH-sensitive hyaluronan nanoparticles for delivery of iridium(III) anticancer drugsBiomacromolecules2017187 2102 211728605176
   PubMed Web of Science ®Google Scholar
• WangYWangJYuanZChitosan cross-linked poly(acrylic acid) hydrogels: drug release control and mechanismColloids Surf B Biointerfaces2017152 252 25928119220
   PubMed Web of Science ®Google Scholar
• ZhangXWangYZhaoYSunLpH-responsive drug release and real-time fluorescence detection of porous silica nanoparticlesMater Sci Eng C Mater Biol Appl201777 19 2628532020
   PubMed Web of Science ®Google Scholar
• KommareddySAmijiMPoly(ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA deliveryNanomedicine200731 32 4217379167
   PubMed Web of Science ®Google Scholar
• LiuBHanLLiuJHanSChenZJiangLCo-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancerInt J Nanomedicine201712 955 96828203075
   PubMed Web of Science ®Google Scholar
• LiCLiHWangQpH-sensitive polymeric micelles for targeted delivery to inflamed jointsJ Control Release2017246 133 14128038947
   PubMed Web of Science ®Google Scholar
• HeYSuZXueLXuHZhangCCo-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapyJ Control Release2016229 80 9226945977
   PubMed Web of Science ®Google Scholar
• MandalBMittalNKBalabathulaPThomaLAWoodGCDevelopment and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancerEur J Pharm Sci201681 162 17126517962
   PubMed Web of Science ®Google Scholar
• FathiMZangabadPSAghanejadABararJErfan-NiyaHOmidiYFolate-conjugated thermosensitive O-maleoyl modified chitosan micellar nanoparticles for targeted delivery of erlotinibCarbohydr Polym2017172 130 14128606519
   PubMed Web of Science ®Google Scholar
• LvSTangZLiMCo-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancerBiomaterials20143523 6118 612924794923
   PubMed Web of Science ®Google Scholar
• LinXWangZJWangSComparison of tissue distribution of a PEGylated radix ophiopogonis polysaccharide in mice with normal and ischemic myocardiumEur J Pharm Biopharm2011793 621 62621784151
   PubMed Web of Science ®Google Scholar
• KimCELimSKKimJSIn vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancerJ Control Release20121572 190 19521963773
   PubMed Web of Science ®Google Scholar
• MarslinGSheebaCJKalaichelvanVKManavalanRReddyPNFranklinGPoly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces Erlotinib-induced subacute toxicity in ratJ Biomed Nanotechnol200955 464 47120201419
   PubMed Web of Science ®Google Scholar
• BakhtiaryZBararJAghanejadAMicroparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancerDrug Dev Ind Pharm2017438 1244 125328323493
   PubMed Web of Science ®Google Scholar
• YanJWangYZhangXLiuSTianCWangHTargeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivoDrug Deliv2016235 1757 176226203689
   PubMed Web of Science ®Google Scholar
• LuZSuJLiZZhanYYeDHyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapyDrug Dev Ind Pharm2017431 160 17027553814
   PubMed Web of Science ®Google Scholar
• NiSQiuLZhangGZhouHHanYLymph cancer chemotherapy: delivery of doxorubicin-gemcitabine prodrug and vincristine by nano-structured lipid carriersInt J Nanomedicine201712 1565 157628280326
   PubMed Web of Science ®Google Scholar